CAS 118675-50-6|BW A868C
| Common Name | BW A868C | ||
|---|---|---|---|
| CAS Number | 118675-50-6 | Molecular Weight | 459.578 |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 638.1±65.0 °C at 760 mmHg |
| Molecular Formula | C25H37N3O5 | Melting Point | / |
| MSDS | ChineseUSA | Flash Point | 339.7±34.3 °C |
Names
| Name | 7-[1-benzyl-3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxoimidazolidin-4-yl]heptanoic acid |
|---|---|
| Synonym | More Synonyms |
BW A868C BiologicalActivity
| Description | BW A868C, a hydantoin compound, is a BW245C structural analogue. BW A868C is a selective and potent competitive prostaglandin D2 (PGD2) antagonist. BW A868C has no effect on other prostaglandin receptors (IP, EP1, EP2, TP and FP)[1]. |
|---|---|
| Related Catalog | Research Areas >>Cardiovascular DiseaseSignaling Pathways >>GPCR/G Protein >>Prostaglandin Receptor |
| Target | PGD2 |
| In Vitro | BW A868C antagonizes prosaglandin D2 and BW245C-induced activation of human platelet adenylate cyclase[1]. |
| References | [1]. H Giles, et al. The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist. Br J Pharmacol. 1989 Feb;96(2):291-300. |
Chemical & Physical Properties
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 638.1±65.0 °C at 760 mmHg |
| Molecular Formula | C25H37N3O5 |
| Molecular Weight | 459.578 |
| Flash Point | 339.7±34.3 °C |
| Exact Mass | 459.273315 |
| PSA | 110.18000 |
| LogP | 3.31 |
| Vapour Pressure | 0.0±2.0 mmHg at 25°C |
| Index of Refraction | 1.593 |
| InChIKey | YZJVWSKJHGEIBL-UHFFFAOYSA-N |
| SMILES | O=C(O)CCCCCCC1C(=O)N(Cc2ccccc2)C(=O)N1NCC(O)C1CCCCC1 |
Safety Information
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
Articles28
More Articles| Multiplexed phosphospecific flow cytometry enables large-scale signaling profiling and drug screening in blood platelets. J. Thromb. Haemost. 12(10) , 1733-43, (2014) Dissecting the signaling events that contribute to platelet activation will increase our understanding of platelet function and aid in the development of new antiplatelet agents. However, high-through... | |
| Genetic validation of a therapeutic target in a mouse model of ALS. Sci. Transl. Med. 6(248) , 248ra104, (2014) Neurons produced from stem cells have emerged as a tool to identify new therapeutic targets for neurological diseases such as amyotrophic lateral sclerosis (ALS). However, it remains unclear to what e... | |
| Pro-migratory actions of the prostacyclin receptor in human breast cancer cells that over-express cyclooxygenase-2. Biochem. Pharmacol. 96 , 306-14, (2015) Metastasis is the major cause of death in cancer patients. Elevated expression of cyclooxygenase-2 (COX-2) is observed in many human cancers and over-production of downstream prostaglandins (PGs) has ... |
Synonyms
| 4-Imidazolidineheptanoic acid, 3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxo-1-(phenylmethyl)- |
| BW A868C |
| 3-[(2-Cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxo-1-(phenylmethyl)- 4-imidazolidineheptanoic acid |
| 7-{1-Benzyl-3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxo-4-imidazolidinyl}heptanoic acid |
| 7-{1-Benzyl-3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxoimidazolidin-4-yl}heptanoic acid |
